Fundamental aspects of both neurological and reproductive function are established in fetal life, and there is a present increased awareness of the potential effects of fetal exposures on neurodevelopmental and reproductive health of offspring. Experimental and epidemiological research studies strongly suggest that paracetamol and NSAID are endocrine disruptive in the fetus, which could increase the risks of some neurodevelopmental, reproductive, and urogenital disorders. In recent years, there has been an increasing rate of neurodevelopmental disorders such as ADHD and autism. The original cohort, the Copenhagen Analgesic Study (COPANA), is the first prospective human study designed primarily to assess the effect of fetal exposure to mild analgesics on male and female reproductive function. If the same children are examined with relevant neurobehavioral testing during mid-childhood, the study design allows the investigators to assess the effect of mild analgesics as well as other EDCs on neurodevelopmental health.
Age range
2 Years – 6 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Behavior Rating Inventory of Executive Function-Preschool Version (BRIEF-P) (male and female children)
Timeframe: 2-5 years of age
BRIEF-P Global Executive Composite (GEC) (male and female children)
Timeframe: 2-5 years of age
BRIEF-P Emergent Metacognition Index (male and female children)
Timeframe: 2-5 years
Child Behavioral and Emotional Functioning - Child Behavior Checklist (CBCL) - (male and female children)
Timeframe: 2-5 years of age
CBCL Total Problem Score (TPS) (male and female children)
Timeframe: 2-5 years of age
CBCL Internalizing Score (male and female children)
Timeframe: 2-5 years of age
CBCL Externalizing Score (male and female children)
Timeframe: 2-5 years of age
Danish MacArthur-Bates Communicative Development Inventories (MB-CDI) (male and female children)
Timeframe: 2-4 years
MB-CDI Vocabulary Size (Words Understood and Produced) (male and female children)
Timeframe: 2-4 years
MB-CDI Sentence and Grammar Use (male and female children)
Timeframe: 2-4 years of age
Preschool Activities Inventory - Gender-typical behavior (male and female children)
Timeframe: 3-5 years
Attention deficit hyperactivity disorder (ADHD) symptom load - Measured by the ADHD Rating Scale (male and female children)
Timeframe: At 5 years of age
Inattention symptom load - Measured by the ADHD Rating Scale (male and female children)
Timeframe: 5 years of age
Hyperactivity/Impulsivity symptom load - Measured by the ADHD Rating Scale (male and female children)
Timeframe: 5 years of age
Total Difficulties Score derived from the "Strengths and Difficulties Questionnaire" (SDQ) (male and female children)
Timeframe: 2-5 years